[Genetic and phenotypic analysis of heterogeneous population of a cold-adapted donor of the A/Leningrad/134/17/57 (H2N2) attenuation and of the donor-based reassortant influenza vaccine strains]

Vopr Virusol. 2005 Mar-Apr;50(2):14-8.
[Article in Russian]

Abstract

Cold-adapted (CA) temperature sensitive and attenuated virus A/Leningrad/134/17/57 (H2N2) (Len/17) has been recently used in Russia as a donor of internal genes in the preparation of reassortant vaccine strains of CA live influenza vaccine (LIV) for all age groups. The Len/17 population was found to be heterogeneous and to be made up of clones, which differ by combinations of mutations in internal genes. Around 50% of the Len/17 population had clones with all 8 coding mutations in internal genes. The others were made up of clones with mutation combinations, which were different from the original Len/17. The PCR restriction method was used to analyze 5 clones of Len/17 and 8 LIV vaccine strains. There were no Ala-86-Thr mutation in the M2 protein in 4 clones and 3 vaccine strains. The PB-1 gene of 4 clones and 3 vaccine strains had a mutation encoding Met-317-IIe more typical of a more attenuated virus A/Leningrad/134/47/57 (H2N2) (Len/47). The NP protein of a clone had a mutation Leu-341-IIe also typical of Len/47. However, neither the absence of mutation in the M2 gene nor an extra mutation in the PB1 gene affected the attenuation extent of reassortant CALIV.

Publication types

  • Clinical Trial
  • Comparative Study
  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Cold Temperature
  • Fever / etiology
  • Genotype
  • Humans
  • Influenza A Virus, H2N2 Subtype*
  • Influenza A virus / genetics*
  • Influenza A virus / growth & development
  • Influenza Vaccines / administration & dosage*
  • Influenza Vaccines / adverse effects
  • Influenza Vaccines / genetics*
  • Influenza, Human / prevention & control*
  • Influenza, Human / virology
  • Mutation
  • Nucleoproteins / genetics
  • Phenotype
  • Reassortant Viruses / genetics*
  • Reassortant Viruses / growth & development
  • Vaccination
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / genetics
  • Viral Matrix Proteins / genetics
  • Viral Proteins / genetics

Substances

  • Influenza Vaccines
  • M2 protein, Influenza A virus
  • Nucleoproteins
  • Vaccines, Attenuated
  • Viral Matrix Proteins
  • Viral Proteins
  • influenza virus polymerase basic protein 1